32.46
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
Ultragenyx shares tumble as third quarter earnings fall short of expectations - Investing.com
Ultragenyx sells some royalties on Crysvita to OMERS Life Sciences - Seeking Alpha
Ultragenyx (RARE) Maintains 2025 Financial Guidance and Projects Profitability in 2027 - GuruFocus
Ultragenyx Pharmaceutical Inc Reports Q3 2025 Earnings: EPS of - GuruFocus
RARE's Q3 Revenue Misses Estimates Amid Strategic Advancements - GuruFocus
Ultragenyx Signs $400M Royalty Purchase Agreement - TipRanks
Ultragenyx: Q3 Earnings Snapshot - News-Times
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update - Yahoo Finance
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences - Yahoo Finance
Published on: 2025-11-04 05:38:55 - newser.com
Is Ultragenyx Pharmaceutical Inc. stock attractive for long term wealth buildingQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - newser.com
Will Ultragenyx Pharmaceutical Inc. (UP0) stock hit Wall Street targetsJuly 2025 Technicals & Real-Time Volume Analysis Alerts - newser.com
Can Ultragenyx Pharmaceutical Inc. rally from current levelsM&A Rumor & Safe Entry Trade Reports - newser.com
Is it too late to sell Ultragenyx Pharmaceutical Inc.IPO Watch & Community Verified Trade Signals - newser.com
Published on: 2025-11-04 01:40:43 - newser.com
Is Ultragenyx Pharmaceutical Inc. stock dividend yield sustainableStock Surge & AI Based Buy and Sell Signals - newser.com
Will Ultragenyx Pharmaceutical Inc. stock remain a Wall Street favorite - newser.com
What hedge fund moves indicate for Ultragenyx Pharmaceutical Inc. (UP0) stockRate Cut & Weekly Breakout Watchlists - newser.com
Dosing begins in broader trial of Angelman syndrome therapy - Angelman Syndrome News
Key metrics from Ultragenyx Pharmaceutical Inc.’s quarterly data2025 Market Overview & Technical Pattern Based Signals - newser.com
Why Ultragenyx Pharmaceutical Inc. stock appeals to dividend seekersJuly 2025 Price Swings & Weekly Breakout Stock Alerts - newser.com
Earnings visualization tools for Ultragenyx Pharmaceutical Inc.2025 Support & Resistance & Weekly Momentum Picks - newser.com
Can Ultragenyx Pharmaceutical Inc. (UP0) stock surprise with quarterly results2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - newser.com
Can Ultragenyx Pharmaceutical Inc. (UP0) stock hold up in economic slowdownQuarterly Performance Summary & Daily Volume Surge Signals - newser.com
Is this a good reentry point in Ultragenyx Pharmaceutical Inc.July 2025 Market Mood & Fast Exit and Entry Strategy Plans - newser.com
Is Ultragenyx Pharmaceutical Inc. stock a buy in volatile marketsAnalyst Downgrade & Community Verified Watchlist Alerts - newser.com
Pinnacle Associates Ltd. Sells 29,107 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Chart based analysis of Ultragenyx Pharmaceutical Inc. trends - newser.com
Is Ultragenyx Pharmaceutical Inc. still worth holding after the dipTrade Volume Summary & Verified Chart Pattern Trade Signals - newser.com
Is Ultragenyx Pharmaceutical Inc. stock a top momentum playTrade Entry Summary & High Yield Equity Trading Tips - newser.com
Can Ultragenyx Pharmaceutical Inc. stock sustain revenue growthJuly 2025 Short Interest & Low Risk High Reward Ideas - newser.com
How risky is Ultragenyx Pharmaceutical Inc. stock nowJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
Can Ultragenyx Pharmaceutical Inc. stock deliver sustainable ROEJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
Is Ultragenyx Pharmaceutical Inc. stock attractive after correctionWatch List & Long Hold Capital Preservation Plans - newser.com
Y Intercept Hong Kong Ltd Grows Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Will Ultragenyx Pharmaceutical Inc. see short term momentum2025 Winners & Losers & Weekly Setup with High ROI Potential - newser.com
Will Ultragenyx Pharmaceutical Inc. stock benefit from upcoming earnings reports2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com
Ultragenyx Pharmaceutical Inc expected to post a loss of $1.23 a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL) - The Globe and Mail
Ultragenyx doses first subject in study of GTX-102 for angelman syndrome - Clinical Trials Arena
Emerald Mutual Fund Advisers Trust Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
자본화:
|
볼륨(24시간):